129 related articles for article (PubMed ID: 21484249)
1. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Schultheis B; Strumberg D; Bergmann L; Graeven U; Hanauske AR; Lipp R; Schuette J; Saito K; Scigalla P; Scheulen ME
Invest New Drugs; 2012 Jun; 30(3):1184-92. PubMed ID: 21484249
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Strumberg D; Bergmann L; Graeven U; Hanauske A; Lipp R; Schuette J; Schultheis B; Scigalla P; Urrea P; Scheulen ME
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):470-2. PubMed ID: 20557848
[No Abstract] [Full Text] [Related]
5. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
[TBL] [Abstract][Full Text] [Related]
7. A late phase II study of S-1 for metastatic pancreatic cancer.
Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
10. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
11. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
13. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
14. An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Takezako Y; Morizane C
Oncology; 2005; 68(2-3):171-8. PubMed ID: 16006754
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].
Funakoshi A; Senju T; Sumii T
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1505-9. PubMed ID: 17033248
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution.
Hara F; Kiyoto S; Takahashi M; Takabatake D; Takashima S; Aogi K; Ohsumi S; Takashima S
Oncology; 2010; 79(3-4):273-7. PubMed ID: 21372603
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
Katsumata N; Hirai Y; Kamiura S; Sugiyama T; Kokawa K; Hatae M; Nishimura R; Ochiai K
Ann Oncol; 2011 Jun; 22(6):1353-1357. PubMed ID: 21345941
[TBL] [Abstract][Full Text] [Related]
18. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
19. [S-1 monotherapy for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():207-12. PubMed ID: 16898004
[TBL] [Abstract][Full Text] [Related]
20. A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Morizane C
Jpn J Clin Oncol; 2007 Dec; 37(12):973. PubMed ID: 18211987
[No Abstract] [Full Text] [Related]
[Next] [New Search]
